Premium
Hypermethylation of the COX‐2 gene is a potential prognostic marker for cervical cancer
Author(s) -
Jo Hoenil,
Kang Sokbom,
Kim Jae W.,
Kang Gyeong H.,
Park Noh H.,
Song Yong S.,
Park Sang Y.,
Kang Soon B.,
Lee Hyo P.
Publication year - 2007
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2007.00517.x
Subject(s) - dna methylation , medicine , cdh1 , gene silencing , fhit , cancer , cancer research , gene , cervical cancer , proportional hazards model , oncology , tumor suppressor gene , gene expression , carcinogenesis , biology , genetics , cell , cadherin
Aim: The aim of the present study was to evaluate the DNA hypermethylation profiles of 14 genes known to be associated with tumor behavior and their clinical significance in cervical cancer. Method: The clinical features of 82 patients with stage IB cervical cancer were analyzed in terms of DNA hypermethylation of 14 genes ( hMLH1 , p16 , COX‐2 , CDH1 , APC , DAPK , MGMT , p14 , RASSF1A , RUNX3 , TIMP3 , FHIT , THBS1 , and HLTF ). Results: Of 14 genes investigated, only hypermethylation of COX‐2 showed significant association with poor disease‐free survival ( P = 0.001). To further investigate an alteration in COX‐2 expression by DNA hypermethylation, immunohistochemistry for COX‐2 protein was performed in the cervical cancer tissues. We found no significant association between hypermethylation and expression patterns of the COX‐2 gene. Conclusions: The present results suggest that DNA hypermethylation of the COX‐2 gene may be a potential prognostic marker in early stage cervical cancer, the underlying mechanism of which is independent of gene silencing.